 |
| |
| American Society of Breast Surgeons Release MammoSite Breast Brachytherapy Registry Trial Results
|
| |
| The seven year trial followed over 1,400 patients who were diagnosed with early stage breast cancer and the data confirmed the previously noted excellent results of treatment efficacy, cosmesis and toxicity. |
|
|
MammoSite 5-Day Targeted Radiation Therapy Systems
|
| |
|
|
| Key Findings1 |
|
|
| • |
|
Results compared favorably with other forms of Accelerated Partial Breast Irradiation and Whole Breast Irradiation |
| • |
|
Low rate of local recurrence at 3.8% |
| • |
|
High rate of excellent or good cosmesis at 90.6% |
|
|
|
| |
|
|
| Satisfy your clinical requirements and her need for more convenient care |
|
|
| |
|
|
| Hologic’s 5-Day balloon brachytherapy solutions deliver targeted radiation therapy directly to the area where cancer is most likely to recur, allowing a full course of radiation to be delivered in just five days as compared to five to seven weeks. |
|
| |
|
| |
|
|
| |
1 Shah C, Badiyan S, Ben Wilkinson J, Vicini F, Beitsch P, Keisch M, Arthur D, Lyden M. Treatment Efficacy with Accelerated Partial Breast Irradiation (APBI): Final Analysis of the American Society of Breast Surgeons MammoSite® Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2013 Aug 22. [Epub ahead of print] PubMed PMID: 23975302
2 Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007;194:456–62.
Hologic, MammoSite and associated logos are trademarks and/or registered trademarks of Hologic and/or its subsidiaries in the U.S. and/or other countries. This information is intended for medical professionals in the U.S. and other markets, and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, write to womenshealth@hologic.com.
|
|
|
